Alshammari Fatemah O F O, Al-Saraireh Yousef M, Youssef Ahmed M M, Al-Sarayra Yahya M, Alrawashdeh Hamzeh Mohammad
Department of Medical Laboratory Technology, Faculty of Health Sciences, The Public Authority for Applied Education and Training, Shuwaikh, Kuwait.
Department of Pharmacology, Faculty of Medicine, Mutah University, Al-Karak, Jordan.
Interact J Med Res. 2021 Oct 12;10(4):e31150. doi: 10.2196/31150.
Current standard treatments for patients with recurrent cervical cancer are not very effective and are associated with severe toxicity. Recently, the rational approach for the discovery of new therapies for cervical cancer is based on the alterations in the molecular biology of cancer cells. One of the emerging molecular changes in cancer cells is the aberrant expression of cytochrome P450 1B1 (CYP1B1). This unique enzyme has been reported to be selectively overexpressed in several cancers.
The aim of this study was to examine CYP1B1 expression in cervical cancers and to assess the enzyme's relationship with several clinicopathological features.
Immunohistochemistry was performed to examine CYP1B1 expression in 100 patient samples with cervical cancer and 10 patient samples with normal healthy cervical tissues.
CYP1B1 was expressed in the majority of the cervical cancer samples (91/100, 91.0%) but not in normal healthy cervical samples. The difference in the expression of CYP1B1 between healthy and tumorous cervical tissues was significant (P=.01). Moreover, the frequency of CYP1B1 expression was found to be significantly higher in patients with advanced grades of the disease (P=.03) and in patients having metastasis to the lymph nodes (P=.01). Surprisingly, there was a significantly higher expression of CYP1B1 in patients with a high prevalence of human papilloma virus 16/18 (P=.04).
The differential profile of CYP1B1 expression between cervical cancer tissues and normal cervical tissues suggests that CYP1B1 may be used as a target for future therapeutic exploitations.
复发性宫颈癌患者目前的标准治疗方法效果不佳且伴有严重毒性。近来，发现宫颈癌新疗法的合理途径基于癌细胞分子生物学的改变。癌细胞中一种新出现的分子变化是细胞色素P450 1B1（CYP1B1）的异常表达。据报道，这种独特的酶在几种癌症中选择性过表达。
本研究旨在检测CYP1B1在宫颈癌中的表达，并评估该酶与几种临床病理特征的关系。
采用免疫组织化学法检测100例宫颈癌患者样本和10例正常宫颈组织样本中CYP1B1的表达。
大多数宫颈癌样本（91/100，91.0%）中表达CYP1B1，而正常宫颈样本中未表达。健康宫颈组织与肿瘤宫颈组织中CYP1B1表达的差异具有统计学意义（P = 0.01）。此外，发现疾病晚期患者（P = 0.03）和发生淋巴结转移患者（P = 0.01）中CYP1B1表达频率显著更高。令人惊讶的是，人乳头瘤病毒16/18高流行率患者中CYP1B1表达显著更高（P = 0.04）。
宫颈癌组织与正常宫颈组织中CYP1B1表达的差异情况表明，CYP1B1可能用作未来治疗开发的靶点。
